Literature DB >> 7446501

Intravenous aminophylline in patients with cystic fibrosis. Pharmacokinetics and effect on pulmonary function.

G L Larsen, R J Barron, R A Landay, E K Cotton, M A Gonzalez, J G Brooks.   

Abstract

Intravenous aminophylline was administered to ten patients with cystic fibrosis (CF) to determine if the medication would improve pulmonary function and to study theophylline pharmacokinetics. Intravenous normal saline was given on another day as a control. Thoracic gas volume and airway resistance, measured in a volume displacement body plethysmograph, and maximal expiratory flow-volume curves were performed before and after each infusion. No significant improvement was noted in pulmonary function after normal saline infusion. Following aminophylline infusion. Following aminophylline infusion, significant improvement in thoracic gas volume, residual volume, specific airway conductance, and maximal expiratory flow at 60% of total lung capacity was noted. The pharmacokinetic analysis revealed a mean half-life of 4.7 hours, a total clearance of 91 mL/hr/kg, and a volume of distribution of 574 mL/kg. Intravenous aminophylline can acutely decrease airway obstruction in children with CF.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7446501     DOI: 10.1001/archpedi.1980.02130240027009

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  6 in total

Review 1.  "CF asthma": what is it and what do we do about it?

Authors:  I M Balfour-Lynn; J S Elborn
Journal:  Thorax       Date:  2002-08       Impact factor: 9.139

2.  Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.

Authors:  M LeBel; M G Bergeron; F Vallée; C Fiset; G Chassé; P Bigonesse; G Rivard
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

Review 3.  Clinical pharmacology of antibiotics and other drugs in cystic fibrosis.

Authors:  J Prandota
Journal:  Drugs       Date:  1988-05       Impact factor: 9.546

Review 4.  Treatment of severe small airways disease in children with cystic fibrosis: alternatives to corticosteroids.

Authors:  Adam Jaffe; Ian M Balfour-Lynn
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 5.  Lean body mass as a predictor of drug dosage. Implications for drug therapy.

Authors:  D J Morgan; K M Bray
Journal:  Clin Pharmacokinet       Date:  1994-04       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics in infants and children. A reappraisal.

Authors:  G L Kearns; M D Reed
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.